ArticleJournal of orthopaedic surgery and research2025
Periostin as a diagnostic marker and therapeutic target for intervertebral disc degeneration.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The pathophysiology of intervertebral disc degeneration (IDD), a condition associated with significant morbidity, remains incompletely elucidated. Identification of key proteins that drive IDD progression is crucial for developing effective strategies to mitigate disease advancement. In this study, we discovered that periostin (POSTN) play an important role in IDD through the bioinformatic analysis, and confirmed its presentation in patient nucleus pulposus (NP) tissues and serum samples. Additionally, the serum POSTN level is positively correlated with IDD. To further investigate the functions of POSTN, the nucleus pulposus cells (NPCs) were isolated and stimulated with 10 ng/mL tumor necrosis factor-α (TNF-α) for 48 h as the in vitro disease model. And evaluated by qPCR, western blots, immunofluorescence (IF) staining, transmission electron microscopy and transcriptome sequencing. The data demonstrated that POSTN promotes IDD by inhibiting autophagy in NPCs. The results were validated in vivo through the caudal vertebra needle puncture model of Sprague-Dawley (SD) rats, with X-ray, magnetic resonance imaging (MRI), hematoxylin-eosin (H&E) staining, safranin O-fast green staining, and immunohistochemical staining. In summary, this study demonstrated that POSTN has potential to be a diagnostic marker and therapeutic target for IDD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.